S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
NASDAQ:APYX

Apyx Medical (APYX) Stock Price, News & Analysis

$1.36
-0.06 (-3.90%)
(As of 03:21 PM ET)
Today's Range
$1.33
$1.39
50-Day Range
$1.25
$2.71
52-Week Range
$1.21
$7.97
Volume
113,541 shs
Average Volume
161,433 shs
Market Capitalization
$46.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.17

Apyx Medical MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
356.4% Upside
$6.17 Price Target
Short Interest
Bearish
5.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.07
Upright™ Environmental Score
News Sentiment
-0.34mentions of Apyx Medical in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.68) to ($0.59) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.63 out of 5 stars

Medical Sector

278th out of 938 stocks

Surgical & Medical Instruments Industry

38th out of 97 stocks

APYX stock logo

About Apyx Medical Stock (NASDAQ:APYX)

Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets in the United States and internationally. It operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). The company offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. Its Helium Plasma Technology products are marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It also develops and manufactures hand pieces for open and laparoscopic procedures; and OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

APYX Stock Price History

APYX Stock News Headlines

AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Apyx Medical (APYX) Receives a Hold from JMP Securities
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Q4 2023 Apyx Medical Corp Earnings Call
Apyx: Q4 Earnings Snapshot
APYX Apr 2024 5.000 put
Craig-Hallum Gives a Buy Rating to Codexis (CDXS)
Apyx Medical Corp
See More Headlines
Receive APYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apyx Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2021
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:APYX
Employees
252
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.17
High Stock Price Target
$9.00
Low Stock Price Target
$4.50
Potential Upside/Downside
+356.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-18,710,000.00
Pretax Margin
-40.65%

Debt

Sales & Book Value

Annual Sales
$52.35 million
Book Value
$0.78 per share

Miscellaneous

Free Float
30,106,000
Market Cap
$46.80 million
Optionable
Optionable
Beta
1.13
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

APYX Stock Analysis - Frequently Asked Questions

Should I buy or sell Apyx Medical stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apyx Medical in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" APYX shares.
View APYX analyst ratings
or view top-rated stocks.

What is Apyx Medical's stock price target for 2024?

2 brokers have issued 12-month price objectives for Apyx Medical's stock. Their APYX share price targets range from $4.50 to $9.00. On average, they expect the company's share price to reach $6.17 in the next year. This suggests a possible upside of 356.4% from the stock's current price.
View analysts price targets for APYX
or view top-rated stocks among Wall Street analysts.

How have APYX shares performed in 2024?

Apyx Medical's stock was trading at $2.62 at the start of the year. Since then, APYX shares have decreased by 48.4% and is now trading at $1.3511.
View the best growth stocks for 2024 here
.

When is Apyx Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our APYX earnings forecast
.

How were Apyx Medical's earnings last quarter?

Apyx Medical Co. (NASDAQ:APYX) announced its quarterly earnings results on Thursday, November, 11th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.03. The company earned $11.83 million during the quarter, compared to the consensus estimate of $10.83 million. Apyx Medical had a negative trailing twelve-month return on equity of 54.90% and a negative net margin of 35.75%. During the same quarter last year, the company posted ($0.13) earnings per share.

What guidance has Apyx Medical issued on next quarter's earnings?

Apyx Medical updated its FY 2024 earnings guidance on Thursday, March, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $49.7 million-$52.9 million, compared to the consensus revenue estimate of $59.8 million.

What other stocks do shareholders of Apyx Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apyx Medical investors own include Main Street Capital (MAIN), Johnson & Johnson (JNJ), ONEOK (OKE), Occidental Petroleum (OXY), Procter & Gamble (PG), STORE Capital (STOR), Wells Fargo & Company (WFC), Boeing (BA), Bank of America (BAC) and Delta Air Lines (DAL).

Who are Apyx Medical's major shareholders?

Apyx Medical's stock is owned by a number of retail and institutional investors. Top institutional investors include AIGH Capital Management LLC (5.89%), RTW Investments LP (2.96%), Taylor Frigon Capital Management LLC (1.84%), Silverberg Bernstein Capital Management LLC (1.77%), Raymond James Financial Services Advisors Inc. (1.76%) and Worth Venture Partners LLC (1.50%). Insiders that own company stock include Charles D Goodwin II, Matthew C Hill and Todd Hornsby.
View institutional ownership trends
.

How do I buy shares of Apyx Medical?

Shares of APYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:APYX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners